DTIC THERAPY IN METASTATIC MALIGNANT-MELANOMA - A SIMPLIFIED DOSE SCHEDULE

  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (10-1) , 1123-1126
Abstract
Ninety-seven patients with metastatic malignant melanoma were treated with DTIC [dimethyltriazenoimidazolecarboxamide], 850 mg/m2 given in single doses at 3-6 wk intervals, alone or in combination with cyclophosphamide (750 mg/m2) and vincristine (2 mg/m2) (DCV). Eighteen patients (19%) had objective disease regression, with a median response duration of 151 days. There was no difference in response rate, response duration or survival between the group treated with DTIC alone and the group treated with DCV; there was greater gastrointestinal and hematopoietic toxicity in the DCV group. Tumor regression with this single-dose DTIC regimen is similar to that obtained with 5-day courses of DTIC; toxicity is not increased.

This publication has 0 references indexed in Scilit: